Humanigen Inc. (HGEN)
| Market Cap | 405.75M |
| Revenue (ttm) | 1.83M |
| Net Income (ttm) | -199.42M |
| Shares Out | 58.84M |
| EPS (ttm) | -3.87 |
| PE Ratio | n/a |
| Forward PE | 9.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,580,548 |
| Open | 6.70 |
| Previous Close | 6.66 |
| Day's Range | 6.39 - 6.86 |
| 52-Week Range | 6.03 - 29.20 |
| Beta | -2.38 |
| Analysts | Buy |
| Price Target | 21.71 (+217.9%) |
| Est. Earnings Date | Nov 9, 2021 |
About HGEN
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies t...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for Humanigen stock is "Buy." The 12-month stock price forecast is 21.71, which is an increase of 217.86% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN).
Humanigen Announces Participation and Presentation at Multiple Conferences in September
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
New Strong Sell Stocks for September 14th
ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.
Why Humanigen Stock Is Sinking Today
The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN
NEW YORK , Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. (" Humanigen " or the "Company") (NASDAQ: HGEN).
After FDA Rejection This Biopharma Stock Garners Analyst Downgrades, Price Cuts
JPMorgan has downgraded Humanigen Inc (NASDAQ:HGEN) to Underweight from Neutral and withdrew its price target after the FDA rejected its Emergency Use request for lenzilumab for hospitalized COVID-19 pa...
Why Did Humanigen's Stock Dump Today And What's Next?
Humanigen Inc. (NASDAQ:HGEN) shares are trading sharply lower Thursday after the company announced the FDA declined its EUA request for lenzilumab in hospitalized COVID-19 patients. Humanigen was down 5...
Here's Why Humanigen Is Getting Hammered Today
An attempt to earn authorization for lenzilumab hit a wall at the FDA.
See Why Humanigen Stock Is Plunging To 52-Week Low
The FDA declined Humanigen Inc's (NASDAQ: HGEN) request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized COVID-19 patients. The Company filed its application with...
FDA has declined Humanigen's Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
Implied Volatility Surging for Humanigen (HGEN) Stock Options
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q2 Loss, Misses Revenue Estimates
KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of -160.87% and -98.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the...
Humanigen Reports Second Quarter 2021 Financial Results
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine...
Humanigen's COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without Ventilation
Humanigen Inc (NASDAQ: HGEN) has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19. Data suggested that Black and African-American pat...
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and Africa...
BURLINGAME, Calif.--(BUSINESS WIRE)--Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the ...
BURLINGAME, Calif.--(BUSINESS WIRE)--NIH Advances ACTIV-5/BET-B study to a Phase 2/3 study and modified the primary endpoint to survival without ventilation
Humanigen's Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced its development and commercialization partners for South Korea and the Philippines, Telcon RF Pharmaceu...
Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
UK's MHRA accepts Humanigen's submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling ...
BURLINGAME, Calif.--(BUSINESS WIRE)--UK's MHRA accepts Humanigen's submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
Humanigen Inc. Added to Russell 3000(R) Index
Burlingame, California--(Newsfile Corp. - June 28, 2021) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-res...
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom's Medicines ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced it has initiated a rolling review submission for Marketing Authorization (MA) by the MHRA for its lead drug candidate, lenzilumab
Why This COVID-19 Stock Is On Fire Right Now
While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
Humanigen to Present at the 2021 LD Micro Invitational XI
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces it will present at the 2021 LD Micro Invitational XI
2 Top Biotech Stocks to Buy Right Now
One is growing revenue. And the other may soon launch its first product.